Compound useful for studying birth defects may also have anti-tumour properties

In an interesting bit of scientific serendipity, researchers at North Carolina State University have found that a chemical compound useful for studying the origins of intestinal birth defects may also inhibit the growth and spread of cancerous tumours.

During the screening of chemical compounds created by NC State chemist Dr Alex Deiters, developmental biologist Dr Nanette Nascone-Yoder found one of particular interest to her research: a compound that induced heterotaxia, a disordering or mirror-image 'flipping' of internal organs, in the frog embryos she was studying. Nascone-Yoder is particularly interested in the genetic processes involved in proper formation of the gut tube, which later becomes the intestinal tract.

'For the intestinal tract to form properly, it has to develop asymmetrically. This compound disrupts asymmetry, so it could be quite useful in helping us to determine when and where intestinal development goes wrong in embryos,' Nascone-Yoder says.

But the compound, dubbed 'heterotaxin' by the researchers, had effects beyond just inducing heterotaxia.

'We also noticed that the compound prevents normal blood-vessel formation and prevents cells from migrating by increasing cellular adhesion - basically, the cells are stuck together and can't move.'

Nascone-Yoder and her collaborators searched for known genetic pathways that could regulate all of these different events, and found that the pathway most likely to be affected by heterotaxin was the TGF-beta pathway. TGF-beta is known to play a role in the progression of cancerous tumours from normal to metastatic.

'This was exciting, because tumours have to have cells that can migrate and form a blood supply in order for the cancer to spread,' Nascone-Yoder adds. 'Heterotaxin inhibits those processes, which may make it a good 'lead' candidate for the development of an anti-tumour drug.'

Indeed, collaborative experiments with NC State veterinary oncologist Marlene Hauck and cell biologist Philip Sannes showed that heterotaxin quenches the growth of canine tumour cells, and inhibits some of the changes required for human tumour cells to become migratory and invasive - at least in a petri dish. There is still work to do, but heterotaxin and future synthetic analogues could be the harbinger of a new class of cancer-fighting compounds.

The research is published in the Feb. 24 issue of Chemistry and Biology.